Abstract
Bortezomib shows high activity in light chain amyloidosis. Responses occur rapidly and are seen in cardiac, renal, and hepatic disease. Toxicity in this fragile population is significant.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1456-1457 |
| Number of pages | 2 |
| Journal | Blood |
| Volume | 114 |
| Issue number | 8 |
| DOIs |
|
| State | Published - 2009 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology